DOCSLIB.ORG

Immunomodulation of T Helper Cells by Tumor Microenvironment in Oral

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Immunomodulation of T Helper Cells by Tumor Microenvironment in Oral ORIGINAL RESEARCH published: 07 May 2021 doi: 10.3389/fimmu.2021.643298 Immunomodulation of T Helper Cells by Tumor Microenvironment in Oral Cancer Is Associated With CCR8 Expression and Rapid Membrane Edited by: Vitamin D Signaling Pathway Lewis Z. Shi, University of Alabama at Birmingham, 1 ´ 2 3,4,5 1 United States Marco Fraga , Milly Yañez , Macarena Sherman , Faryd Llerena , Mauricio Hernandez 6, Guillermo Nourdin 6, Francisco A´ lvarez 6, Joaqu´ın Urrizola 7, Reviewed by: Ce´ sar Rivera 8, Liliana Lamperti 1,9, Lorena Nova 10, Silvia Castro 1, Omar Zambrano 11, Hongru Zhang, 11 ´ 12 12 12 12 University of Pennsylvania, Alejandro Cifuentes , Leon Campos , Sergio Moya , Juan Pastor , Marcelo Nuñez , 12 12 ´ 1 ´ 13 14 United States Jorge Gatica , Jorge Figueroa , Felipe Zuñiga , Carlos Salomon , Gustavo Cerda , 5 1 15 16 Greg M. Delgoffe, Ricardo Puentes , Gonzalo Labarca , Mabel Vidal , Reuben McGregor 1 University of Pittsburgh, and Estefania Nova-Lamperti * United States 1 Molecular and Translational Immunology Laboratory, Clinical Biochemistry and Immunology Department, Pharmacy Faculty, *Correspondence: Universidad de Concepcio´ n, Concepcio´ n, Chile, 2 Anatomy Pathology Unit and Dental Service, Oral Pathology Department, Estefania Nova-Lamperti Hospital Las Higueras, Talcahuano, Chile, 3 Anatomy Pathology Unit, Hospital Guillermo Grant Benavente and Universidad [email protected]; de Concepcio´ n, Concepcio´ n, Chile, 4 Head and Neck Service, Hospital Guillermo Grant Benavente, Concepcio´ n, Chile, [email protected] 5 Dental Service, Hospital Guillermo Grant Benavente, Concepcio´ n, Chile, 6 MELISA Institute, San Pedro de la Paz, Chile, 7 Oral Maxillofacial Surgery Department, Dental Faculty, Universidad San Sebastia´ n, Concepcio´ n, Chile, 8 Department of Specialty section: Stomatology, Universidad de Talca, Talca, Chile, 9 PeveGen Laboratory, Concepcio´ n, Chile, 10 Centro de Salud Familiar This article was submitted to (CESFAM) Penco Lirque´ n, Penco, Chile, 11 Surgery Service, Hospital Las Higueras, Talcahuano, Chile, 12 Dental Service, Cancer Immunity and Maxillofacial Surgery Department, Hospital Las Higueras, Talcahuano, Chile, 13 Exosome Biology Laboratory, Centre for Immunotherapy, Clinical Diagnostics, UQ Centre for Clinical Research, Royal Brisbane and Women’s Hospital, Faculty of Medicine + a section of the journal Biomedical Sciences, The University of Queensland, Brisbane, QLD, Australia, 14 Advanced Microscopy Centre, Universidad Frontiers in Immunology de Concepcio´ n, Concepcio´ n, Chile, 15 Computer Science Department, Universidad de Concepcio´ n, Concepcio´ n, Chile, 16 Received: 17 December 2020 Department of Molecular Medicine and Pathology, School of Medical Sciences, The University of Auckland, Auckland, Accepted: 22 April 2021 New Zealand Published: 07 May 2021 Citation: The immune system plays a key role in the protective response against oral cancer; ´ Fraga M, Yañez M, Sherman M, however, the tumor microenvironment (TME) impairs this anti-cancer response by Llerena F, Hernandez M, Nourdin G, A´ lvarez F, Urrizola J, Rivera C, modulating T helper (Th) responses and promoting an anti-inflammatory environment. Lamperti L, Nova L, Castro S, Regulatory T cells (Tregs) and Th2 effector cells (Teff) are associated with poor prognosis Zambrano O, Cifuentes A, Campos L, Moya S, Pastor J, Nuñez M, Gatica J, in oral squamous cell carcinoma (OSCC). However, the main immunomodulatory Figueroa J, Zu´ ñiga F, Salomo´ nC, mechanisms associated with the enrichment of these subsets in OSCC remain Cerda G, Puentes R, Labarca G, unknown. We characterized Th-like lineages in Tregs and Teff and evaluated Vidal M, McGregor R and Nova-Lamperti E (2021) immunomodulatory changes induced by the TME in OSCC. Our phenotypic data Immunomodulation of T Helper Cells revealed a higher distribution of tumour-infiltrating CCR8+ and Th2-like Treg in OSCC by Tumor Microenvironment in Oral Cancer Is Associated With CCR8 compared with non-malignant samples, whereas the percentages of Th1 cells were Expression and Rapid Membrane reduced in cancer. We then analyzed the direct effect of the TME by exposing T cell Vitamin D Signaling Pathway. subsets to cancer secretomes and observed the OSCC secretome induced CCR8 Front. Immunol. 12:643298. doi: 10.3389/fimmu.2021.643298 expression and reduced cytokine production from both subsets. Transcriptomic Frontiers in Immunology | www.frontiersin.org 1 May 2021 | Volume 12 | Article 643298 Fraga et al. T-Cell Immunomodulation in Oral Cancer analysis showed that the co-culture with OSCC secretome induced several gene changes associated with the vitamin D (VitD) signaling pathway in T cells. In addition, proteomic analysis identified the presence of several proteins associated with prostaglandin E2 (PGE2) production by rapid membrane VitD signaling and a reduced presence of the VitD binding protein. Thus, we analyzed the effect of VitD and PGE2 and observed that VitD promotes a regulatory Th2-like response with CCR8 expression whilst PGE2 also modulated CCR8 but inhibited cytokine production in combination with VitD. Finally, we evaluated the presence of CCR8 ligand in OSCC and observed increased chemokine CCL18, which was also able to upregulate CCR8 in activated Th cells. Overall, our data showed the immunomodulatory changes induced by the TME involving CCR8 expression and regulatory Th2 phenotypes, which are associated with PGE2 mediated VitD signaling pathway and CCL18 expression in OSCC. Keywords: oral cancer, immunomodulation, cancer immunology, Th-like Tregs, CCR8 INTRODUCTION higher in low-grade invasive OSCC cell lines than high-grade invasive OSCC cell lines (12, 13). Therefore, novel mechanisms Oral cancer is a malignant neoplasm developed in the oral cavity need to be addressed to understand how this cancer modulates with high mortality and morbidity due to late-stage diagnosis the immune system. In terms of metabolic changes, glycolysis- and high incidence of metastasis (1). Oral squamous cell related proteins and mitochondrial enzymes (14), are also carcinoma (OSCC) is the most common type of oral cancer, significantly increased in the carcinogenesis of OSCC making it representing more than 90% of the cases, and it has been linked is possible that the active glycolytic activity of cancer cells also with uncontrolled proliferation of squamous epithelial cells due affects the function of the immune cells. In terms of the immune to environmental-mediated genetic mutations. Risk factors such repertoire, it has been shown that OSCC includes cells with a as long-term use of tobacco, alcohol abuse, excessive sun pro-tumoral role such as tumor associated macrophages exposure, human papillomavirus (HPV) infection and a (TAMs), cancer-associated fibroblasts (CAF) and regulatory T weakened immune system have been associated with OSCC (2, cells (Tregs) (11). 3). In fact, it has been proposed that the origin of oral cancer is Previous data from our lab characterized the Th-like Tregs associated with DNA alteration mediated by environmental based on the expression of three chemokine receptors, immune carcinogens, since 3 to 6 mutations are required to transform a transcriptomic profiles and specific lineage cytokine production, healthy cell to a malignant cell (4). It is the impaired or defining Th1 as CXCR3+CCR6-CCR4+, Th2 as CXCR3-CCR6- overwhelmed anti-tumor immune response in the patient is CCR4+,Th17asCXCR3-CCR6+CCR4+ and Th1/17 the main factor that favors subsequent tumor progression (5). CXCR3+CCR6+CCR4+ (15). We found that Th2-like Tregs This altered response is not only associated with cancer expressed CCR8 and exhibited higher viability than other Th- cells escaping the immune control, but also to the like Tregs subsets, however suppression capacity was similar immunomodulatory effects of the tumor microenvironment by between subsets. However, Th2-like Tregs and Th2 Teff migrated contact dependent and soluble mechanisms, promoting a more than other Th-like subsets a phenomenon not mediated by regulatory immune repertoire and inducing an anti- CCR4 expression. Finally, we analyzed the presence of Th-like inflammatory environment. Tregs in blood, thymus, spleen, liver, skin, colon and tissues and The immunomodulatory mechanisms exerted by the tumor blood from patients with melanoma and colon cancer. We microenvironment include the contribution of cancer-associated observed a high presence of Th2-like Tregs and Th2 effector immune cells, the expression of inhibitory checkpoints (6) and cells (Teff) in melanoma and colorectal cancer at late-stage. Here the production of soluble factors such as proteins, metabolites, we progress these findings by investigating the distribution of chemical factors (7–9) and extracellular vesicles (10). In OSCC, these subsets in a cancer that has been traditionally associated the presence of cytokines such as IL-4, IL-5, IL-10, TGF-b, IL-17, with late-stage detection to evaluate if there is a specific subset IL-1a and immune-checkpoint inhibitors such as PD-L1 and enriched in well-established tumors and the main mechanism Indoleamine 2,3-Dioxygenase 1 (IDO1) have been associated associated with the enrichment of Th2 subsets in cancer areas. with poor prognosis (11). Several chemokines have also been In this study we analyzed the distribution of tissue resident associated with immunomodulation in OSCC such as CCL18, Th-like Tregs and Teff in OSCC compared to non-malignant CXCL13 and CCL4. It is however not clear whether the biopsies allowing us to investigate
Load more

Recommended publications
  • Complementary DNA Microarray Analysis of Chemokines and Their Receptors in Allergic Rhinitis RX Zhang,1 SQ Yu,2 JZ Jiang,3 GJ Liu3
    RX Zhang, et al ORIGINAL ARTICLE Complementary DNA Microarray Analysis of Chemokines and Their Receptors in Allergic Rhinitis RX Zhang,1 SQ Yu,2 JZ Jiang,3 GJ Liu3 1 Department of Otolaryngology, Huadong Hospital, Fudan University, Shanghai, China 2 Department of Otolaryngology , Jinan General Hospital of PLA, Shandong, China 3 Department of Otolaryngology, Changhai Hospital, Second Military Medical University, Shanghai, China ■ Abstract Objective: To analyze the roles of chemokines and their receptors in the pathogenesis of allergic rhinitis by observing the complementary DNA (cDNA) expression of the chemokines and their receptors in the nasal mucosa of patients with and without allergic rhinitis, using gene chips. Methods: The total RNAs were isolated from the nasal mucosa of 20 allergic rhinitis patients and purifi ed to messenger RNAs, and then reversely transcribed to cDNAs and incorporated with samples of fl uorescence-labeled with Cy5-dUPT (rhinitis patient samples) or Cy3- dUTP (control samples of nonallergic nasal mucosa). Thirty-nine cDNAs of chemokines and their receptors were latticed into expression profi le chips, which were hybridized with probes and then scanned with the computer to study gene expression according to the different fl uorescence intensities. Results: The cDNAs of the following chemokines were upregulated: CCL1, CCL2, CCL5, CCL7, CCL8, CCL11, CCL13, CCL14, CCL17, CCL18, CCL19, CCL24, and CX3CL1 in most of the allergic rhinitis sample chips. CCR2, CCR3, CCR4, CCR5, CCR8 and CX3CR1 were the highly expressed receptor genes. Low expression of CXCL4 was found in these tissues. Conclusion: The T helper cell (TH) immune system is not well regulated in allergic rhinitis.
    [Show full text]
  • Cancer Immunology, Immunotherapy Editor-In-Chief: H
    Cancer Immunology, Immunotherapy Editor-in-Chief: H. Dong ▶ 94% of authors who answered a survey reported that they would definitely publish or probably publish in the journal again Since its inception in 1976, Cancer Immunology, Immunotherapy (CII) has reported significant advances in the field of tumor immunology. The journal serves as a forum for new concepts and advances in basic, translational, and clinical cancer immunology and immunotherapy. CII is keen to publish broad-ranging ideas and reviews, results which extend or challenge established paradigms, as well as negative studies which fail to reproduce experiments that support current paradigms, and papers that do succeed in reproducing others’ results in different contexts. Cll is especially interested in papers describing clinical trial designs and outcome regardless of whether they met their designated endpoints or not, and particularly those shedding light on immunological mechanisms. CII is affiliated with the Association for Cancer Immunotherapy (CIMT), Canadian Cancer 12 issues/year Immunotherapy Consortium (CCIC), The Japanese Association for Cancer Immunology (JACI), Network Italiano per la Bioterapia dei Tumori (NIBIT),and Sociedad Española de Inmunologia- Electronic access Grupo Española de InmunoTerapia (SEI-GEIT). ▶ link.springer.com CIMT: http://www.cimt.eu/home Subscription information CCIC: http://www.immunotherapycancer.ca/ ▶ springer.com/librarians JACI: http://www.jaci.jp/eng/index.html NIBIT: http://www.nibit.org/index.php SEI-GEIT: http://www.inmunologia.org/grupos/home.php? UpOm5=M&Upfqym5uom=GK CITIM: http://www.canceritim.org Impact Factor: 6.968 (2020), Journal Citation Reports® On the homepage of Cancer Immunology, Immunotherapy at springer.com you can ▶ Sign up for our Table of Contents Alerts ▶ Get to know the complete Editorial Board ▶ Find submission information.
    [Show full text]
  • Prospects for NK Cell Therapy of Sarcoma
    cancers Review Prospects for NK Cell Therapy of Sarcoma Mieszko Lachota 1 , Marianna Vincenti 2 , Magdalena Winiarska 3, Kjetil Boye 4 , Radosław Zago˙zd˙zon 5,* and Karl-Johan Malmberg 2,6,* 1 Department of Clinical Immunology, Doctoral School, Medical University of Warsaw, 02-006 Warsaw, Poland; [email protected] 2 Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, 0310 Oslo, Norway; [email protected] 3 Department of Immunology, Medical University of Warsaw, 02-097 Warsaw, Poland; [email protected] 4 Department of Oncology, Oslo University Hospital, 0310 Oslo, Norway; [email protected] 5 Department of Clinical Immunology, Medical University of Warsaw, 02-006 Warsaw, Poland 6 Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, 141 86 Stockholm, Sweden * Correspondence: [email protected] (R.Z.); [email protected] (K.-J.M.) Received: 15 November 2020; Accepted: 9 December 2020; Published: 11 December 2020 Simple Summary: Sarcomas are a group of aggressive tumors originating from mesenchymal tissues. Patients with advanced disease have poor prognosis due to the ineffectiveness of current treatment protocols. A subset of lymphocytes called natural killer (NK) cells is capable of effective surveillance and clearance of sarcomas, constituting a promising tool for immunotherapeutic treatment. However, sarcomas can cause impairment in NK cell function, associated with enhanced tumor growth and dissemination. In this review, we discuss the molecular mechanisms of sarcoma-mediated suppression of NK cells and their implications for the design of novel NK cell-based immunotherapies against sarcoma.
    [Show full text]
  • The Journal of the International Federation of Clinical Chemistry and Laboratory Medicine in This Issue
    June 2021 ISSN 1650-3414 Volume 32 Number 2 Communications and Publications Division (CPD) of the IFCC Editor-in-chief: Prof. János Kappelmayer, MD, PhD Faculty of Medicine, University of Debrecen, Hungary e-mail: [email protected] The Journal of the International Federation of Clinical Chemistry and Laboratory Medicine In this issue Introducing the eJIFCC special issue on “POCT – making the point” Guest editor: Sergio Bernardini 116 Controlling reliability, interoperability and security of mobile health solutions Damien Gruson 118 Best laboratory practices regarding POCT in different settings (hospital and outside the hospital) Adil I. Khan 124 POCT accreditation ISO 15189 and ISO 22870: making the point Paloma Oliver, Pilar Fernandez-Calle, Antonio Buno 131 Utilizing point-of-care testing to optimize patient care James H. Nichols 140 POCT: an inherently ideal tool in pediatric laboratory medicine Siobhan Wilson, Mary Kathryn Bohn, Khosrow Adeli 145 Point of care testing of serum electrolytes and lactate in sick children Aashima Dabas, Shipra Agrawal, Vernika Tyagi, Shikha Sharma, Vandana Rastogi, Urmila Jhamb, Pradeep Kumar Dabla 158 Training and competency strategies for point-of-care testing Sedef Yenice 167 Leading POCT networks: operating POCT programs across multiple sites involving vast geographical areas and rural communities Edward W. Randell, Vinita Thakur 179 Connectivity strategies in managing a POCT service Rajiv Erasmus, Sumedha Sahni, Rania El-Sharkawy 190 POCT in developing countries Prasenjit Mitra, Praveen Sharma 195 In this issue How could POCT be a useful tool for migrant and refugee health? Sergio Bernardini, Massimo Pieri, Marco Ciotti 200 Direct to consumer laboratory testing (DTCT) – opportunities and concerns Matthias Orth 209 Clinical assessment of the DiaSorin LIAISON SARS-CoV-2 Ag chemiluminescence immunoassay Gian Luca Salvagno, Gianluca Gianfilippi, Giacomo Fiorio, Laura Pighi, Simone De Nitto, Brandon M.
    [Show full text]
  • Bioinformatics Identification of CCL8/21 As Potential Prognostic
    Bioscience Reports (2020) 40 BSR20202042 https://doi.org/10.1042/BSR20202042 Research Article Bioinformatics identification of CCL8/21 as potential prognostic biomarkers in breast cancer microenvironment 1,* 2,* 3 4 5 1 Bowen Chen , Shuyuan Zhang ,QiuyuLi, Shiting Wu ,HanHe and Jinbo Huang Downloaded from http://portlandpress.com/bioscirep/article-pdf/40/11/BSR20202042/897847/bsr-2020-2042.pdf by guest on 28 September 2021 1Department of Breast Disease, Maoming People’s Hospital, Maoming 525000, China; 2Department of Clinical Laboratory, Maoming People’s Hospital, Maoming 525000, China; 3Department of Emergency, Maoming People’s Hospital, Maoming 525000, China; 4Department of Oncology, Maoming People’s Hospital, Maoming 525000, China; 5Department of Medical Imaging, Maoming People’s Hospital, Maoming 525000, China Correspondence: Shuyuan Zhang ([email protected]) Background: Breast cancer (BC) is the most common malignancy among females world- wide. The tumor microenvironment usually prevents effective lymphocyte activation and infiltration, and suppresses infiltrating effector cells, leading to a failure of the host toreject the tumor. CC chemokines play a significant role in inflammation and infection. Methods: In our study, we analyzed the expression and survival data of CC chemokines in patients with BC using several bioinformatics analyses tools. Results: The mRNA expression of CCL2/3/4/5/7/8/11/17/19/20/22 was remark- ably increased while CCL14/21/23/28 was significantly down-regulated in BC tis- sues compared with normal tissues. Methylation could down-regulate expression of CCL2/5/15/17/19/20/22/23/24/25/26/27 in BC. Low expression of CCL3/4/23 was found to be associated with drug resistance in BC.
    [Show full text]
  • Engineered Marrow Macrophages for Cancer Therapy: Engorgement, Accumulation, Differentiation, and Acquired Immunity
    University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations 2017 Engineered Marrow Macrophages For Cancer Therapy: Engorgement, Accumulation, Differentiation, And Acquired Immunity Cory Alvey University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Pharmacology Commons Recommended Citation Alvey, Cory, "Engineered Marrow Macrophages For Cancer Therapy: Engorgement, Accumulation, Differentiation, And Acquired Immunity" (2017). Publicly Accessible Penn Dissertations. 2164. https://repository.upenn.edu/edissertations/2164 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/2164 For more information, please contact [email protected]. Engineered Marrow Macrophages For Cancer Therapy: Engorgement, Accumulation, Differentiation, And Acquired Immunity Abstract The ability of a macrophage to engulf and break down invading cells and other targets provides a first line of immune defense in nearly all tissues. This defining ability ot ‘phagos’ or devour can subsequently activate the entire immune system against foreign and diseased cells, and progress is now being made on a decades-old idea of directing macrophages to phagocytose specific targets such as cancer cells. Physical properties of cancer cells influence phagocytosis and relate via cytoskeleton forces to differentiation pathways in solid tumors. Here, SIRPα on macrophages from mouse and human marrow was inhibited to block recognition of CD47, a ‘marker of self.’ These macrophages were then systemically injected into mice with fluorescent human tumors. Within days, the tumors regressed, and fluorescence analyses showed that the more the SIRPα-inhibited macrophages engulfed, the more they accumulated within tumors. In vitro phagocytosis experiments on transwells revealed that macrophage migration through micropores was inhibited by eating.
    [Show full text]
  • Immunotherapy, Inflammation and Colorectal Cancer
    cells Review Immunotherapy, Inflammation and Colorectal Cancer Charles Robert Lichtenstern 1,2, Rachael Katie Ngu 1,2, Shabnam Shalapour 1,2,* and Michael Karin 1,2,3 1 Department of Pharmacology, School of Medicine, University of California, San Diego, La Jolla, CA 92093, USA; karinoffi[email protected] 2 Laboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, School of Medicine, University of California, San Diego, La Jolla, CA 92093, USA 3 Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA * Correspondence: [email protected] Received: 30 January 2020; Accepted: 3 March 2020; Published: 4 March 2020 Abstract: Colorectal cancer (CRC) is the third most common cancer type, and third highest in mortality rates among cancer-related deaths in the United States. Originating from intestinal epithelial cells in the colon and rectum, that are impacted by numerous factors including genetics, environment and chronic, lingering inflammation, CRC can be a problematic malignancy to treat when detected at advanced stages. Chemotherapeutic agents serve as the historical first line of defense in the treatment of metastatic CRC. In recent years, however, combinational treatment with targeted therapies, such as vascular endothelial growth factor, or epidermal growth factor receptor inhibitors, has proven to be quite effective in patients with specific CRC subtypes. While scientific and clinical advances have uncovered promising new treatment options, the five-year survival rate for metastatic CRC is still low at about 14%. Current research into the efficacy of immunotherapy, particularly immune checkpoint inhibitor therapy (ICI) in mismatch repair deficient and microsatellite instability high (dMMR–MSI-H) CRC tumors have shown promising results, but its use in other CRC subtypes has been either unsuccessful, or not extensively explored.
    [Show full text]
  • 1995) Borrelia Burgdorferi-Specific T Lymphocytes Induce Severe Destructive Lyme Arthritis
    LTT (Lymphozyten-Proliferationstest, „Lymphozyten-Transformationstest“) Interferon Gamma Test, ELISpot (T-Cell Spot), dem Lymphozytentransformationstest bei Borreliose und bei anderen Infektionskrankheiten Im Lymphozyten-Proliferationstest, auch Lymphozyten-Transformationstest genannt (LTT), wird die Proliferationskapazität von Lymphozyten dargestellt. Der Test dient der Bewertung des Immunstatus oder der Diagnose einer speziellen Sensibilisierung. In the Lymphocyte proliferation assay, also known as lymphocyte transformation test (LTT), the proliferation capacity of lymphocytes is shown. The test is used to evaluate the immune status or the diagnosis of specific sensitization of an object. Im Interferon Gamma Test, dem ELISPOT (Enzyme-Linked ImmunoSpot), auch T- Cellspot genannt, wird durch die Bestimmung der Zytokin – Produktion die Quantität und die Qualität einer T – Zell - Immunantwort zeitnah dokumentiert. In the Interferone Gamma Test, ELISPOT (Enzyme-Linked ImmunoSpot), also called T-Cell spot, represented by the determination of cytokine – Production, the quantity and quality of T - cell - immune response in a timely manner is documented. Lim LC, England DM, DuChateau BK, Glowacki NJ, Schell RF (1995) Borrelia burgdorferi-specific T lymphocytes induce severe destructive Lyme arthritis. Infect. Immun. 63, 1400-1408. Dwyer JM et al. (1979) Behavior of human immunoregulatory cells in culture. L Variables requiring consideration for clinical studies. Clin Exp Immunol 38, 499-513 Johnson C, Dwyer JM (1981) Quantitation of spontaneous suppressor cell activity in human cord blood lymphocytes and their behavior in culture (abstract). Fed Proc 40, 1075 Czerkinsky C, Nilsson L, Nygren H, Ouchterlony O, Tarkowski A (1983) A solid-phase enzyme- linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells.J Immunol Methods 65 (1–2), 109–121.
    [Show full text]
  • Innate Immunity and Inflammation
    ISBTc ‐ Primer on Tumor Immunology and Biological Therapy of Cancer InnateInnate ImmunityImmunity andand InflammationInflammation WillemWillem Overwijk,Overwijk, Ph.D.Ph.D. MDMD AndersonAnderson CancerCancer CenterCenter CenterCenter forfor CancerCancer ImmunologyImmunology ResearchResearch Houston,Houston, TXTX www.allthingsbeautiful.com InnateInnate ImmunityImmunity andand InflammationInflammation • Definitions • Cells and Molecules • Innate Immunity and Inflammation in Cancer • Bad Inflammation • Good Inflammation • Therapeutic Implications InnateInnate ImmunityImmunity andand InflammationInflammation • Definitions • Cells and Molecules • Innate Immunity and Inflammation in Cancer • Bad Inflammation • Good Inflammation • Therapeutic Implications • Innate Immunity: Immunity that is naturally present and is not due to prior sensitization to an antigen; generally nonspecific. It is in contrast to acquired/adaptive immunity. Adapted from Merriam‐Webster Medical Dictionary • Innate Immunity: Immunity that is naturally present and is not due to prior sensitization to an antigen; generally nonspecific. It is in contrast to acquired/adaptive immunity. • Inflammation: a local response to tissue injury – Rubor (redness) – Calor (heat) – Dolor (pain) – Tumor (swelling) Adapted from Merriam‐Webster Medical Dictionary ““InnateInnate ImmunityImmunity”” andand ““InflammationInflammation”” areare vaguevague termsterms •• SpecificSpecific cellcell typestypes andand moleculesmolecules orchestrateorchestrate specificspecific typestypes ofof inflammationinflammation
    [Show full text]
  • Metastasis: Active Lymph Nodes
    RESEARCH HIGHLIGHTS METASTASIS subcapsular sinus. Further investiga- tions in vivo revealed that CCR8 acti- vation in tumour cells was required Active lymph nodes for tumour cell extravasation from lymphatic vessels, specifically for the Lymph node metastases are CCL1 activates CCR8-mediated transmigration of tumour cells from indicative of poor prognosis but intracellular signalling in tumour the subcapsular sinus into the lymph tumour cell the mechanisms of tumour cell cells, which resulted in cellular node cortex. entry into the dissemination via the lymphatics changes that are consistent with cell These data unpick the process of are poorly understood. Although it migration. lymphatic dissemination and iden- lymph node is widely believed that tumour cells Is the CCR8–CCL1 paracrine tify the sequence of steps leading to requires active enter the lymph nodes passively with pathway important in lymphatic lymph node metastasis. The authors cell migration the flow of lymph, previous data have metastasis? The suppression of showed that CCR8 is expressed by indicated that some chemokines may CCR8 expression or activity in a large subset of human melanoma promote lymphatic extravasation human melanoma cells did not samples, and it will be interesting and metastasis. Das et al. now dem- affect tumour growth or vasculariz­ to determine whether this pathway onstrate that tumour cell entry into ation on implantation into immuno­ can be targeted to prevent lymph the lymph node requires active cell deficient mice, but significantly node metastasis. migration and they also identify the reduced the incidence of lymph Gemma K. Alderton lymphatic endothelium of the lymph node metastasis. Furthermore, ORIGINAL RESEARCH PAPER Das, S.
    [Show full text]
  • Principles of Tumour Immunology
    Principles of tumour immunology Michele Teng Nov 20th 2017, Singapore Cancer Immunoregulation and Immunotherapy Laboratory QIMR Berghofer MRI Brisbane, Australia [email protected] Disclosure Slide • I have received speakers bureau honoria from Merck Sharp & Dohme. Talk Outline 1. Hallmarks of Cancer 2. Cells of the Immune system 3. The Cancer Immunity Cycle - Tumor-associated antigens (TAA), Cellular and Humoral responses to TAA 4. Conceptual developments in the field of tumour immunology - Immunosurveillance and role of innate immunity, immune balance against cancer Sources of slide • Charles Janeway’s Immunobiology text book • Peer-reviewed articles (Pubmed) • Online slides ( URL listed) Cancer Hallmarks of Cancer (2000) Hanahan and Weinberg, Cell 2000 Emerging Hallmarks and Enabling Characteristics Hanahan and Weinberg, Cell 2011 Hallmarks of Cancer (2017) In Vitrogen Immunology (Study of the immune system) Cells of the immune system ILCs –innate lymphoid cells MAITs –Mucosal associated invariant T cells gd T cells – gamma delta T cells (ILCs) (gd, MAIT) Cancer Immunology (Study of the response of the immune system to cancer) The Cancer-Immunity Cycle – Steps to generate an effective anti-tumour response Chen and Mellman Immunity 2013 Not all cell deaths are equal (at priming an immune response) Cells can die in different ways DAMPs Tumour fragments Immunogenic Cell Death (ICD) DAMPs – Damage (Adjuvanticity, Antigenicity) associated molecular patterns Differential requirements for the immunogenicity of cell death TLR4 Nat Rev Immunol. 2017 Feb;17(2):97-111. doi: 10.1038/nri.2016.107. The Cancer-Immunity Cycle Immunity. 2013 Jul 25;39(1):1-10. doi: 10.1016/j.immuni.2013.07.012.
    [Show full text]
  • Identification of CCL1 As a Gene Differentially Expressed in CD4＋ T Cells Expressing TIM-3
    http://dx.doi.org/10.4110/in.2011.11.4.203 ORIGINAL ARTICLE pISSN 1598-2629 eISSN 2092-6685 Identification of CCL1 as a Gene Differentially Expressed in CD4＋ T cells Expressing TIM-3 Ka Jung Jun1,2, Mi Jin Lee1,2, Dong Chul Shin1,2, Min Yeong Woo1,2, Kyongmin Kim1 and Sun Park1* 1Department of Microbiology and 2Graduate Program of Molecular Medicine, Ajou University School of Medicine, Suwon 442-749, Korea Background: T cell immunoglobulin mucin containing mole- responses and the pathogenesis of several diseases (1). With cule (TIM)-3 is expressed in differentiated Th1 cells and is in- its blocking antibody or its soluble fusion protein TIM-3-Ig, volved in the suppression of the cytokine production by these Th1 immune response as well as anti-tumor immunity is en- cells. However, the regulation of the expression of other T hanced (2-4). Also, induction of tolerance in an experimental cell genes by TIM-3 is unclear. Herein, we attempted to iden- transplantation model is abrogated by injection of TIM-3 anti- tify differentially expressed genes in cells abundantly ex- body (5). Furthermore, dysregulation of T cell TIM-3 ex- pressing TIM-3 compared to cells with low expression of pression is observed in several autoimmune diseases includ- TIM-3. Methods: TIM-3 overexpressing cell clones were es- ing multiple sclerosis, rheumatoid arthritis and Crohn s dis- tablished by transfection of Jurkat T cells with TIM-3 ex- ’ pression vector. For screening of differentially expressed ease (6-8). genes, gene fishing technology based on reverse tran- Galectin-9 and phosphatidylserine have been identified as scription-polymerase chain reaction (RT-PCR) using an an- TIM-3 ligands.
    [Show full text]